Analysis of indications and effects of regorafenib in the treatment of various cancers

Regorafenib is an oral multi-target tyrosine kinase inhibitor that can simultaneously inhibit multiple kinases related to tumor growth and angiogenesis. With its broad-spectrum targeting mechanism, regorafenib is approved for the treatment of a variety of advanced malignant tumors, especially playing an important role in second- or third-line treatment after some conventional treatment options fail. Its multiple target effects give regorafenib unique advantages in anti-tumor, anti-angiogenesis and anti-tumor microenvironment regulation.

Regofenib has become a standard late-line treatment option in the treatment of advanced colorectal cancer. Multiple clinical trials have shown that for patients whose disease has progressed after treatment with chemotherapy drugs such as fluorouracil, oxaliplatin, and irinotecan, regorafenib can significantly prolong overall survival (OS) and progression-free survival (PFS) and improve patients' quality of life. Its ability to inhibit tumor angiogenesis can effectively block the nutrient supply of tumors and inhibit the continued development of tumors.

In addition to colorectal cancer, regorafenib is also widely used in the treatment of hepatocellular carcinoma (HCC). As an important treatment for patients with advanced liver cancer, regorafenib can significantly delay disease progression, and is especially suitable for patients who are resistant to sorafenib treatment or cannot tolerate sorafenib. Multiple studies have shown that regorafenib has a significant effect in prolonging the overall survival time and improving the quality of life of patients, making it an important part of the treatment of liver cancer.

In addition, regorafenib is also approved for the treatment of patients with gastrointestinal stromal tumors (GIST), especially those who are resistant to imatinib and sematinib. By blocking multiple signaling pathways, regorafenib can control tumor growth and delay disease progression. Overall, regorafenib has shown good efficacy in the treatment of a variety of refractory tumors due to its multi-target inhibitory effect, and is an important treatment option for patients with a variety of advanced cancers.

Reference materials:https://www.stivarga-us.com/